Zimmer Biomet Holdings, Inc. has announced its financial results for the first quarter of 2024, with net sales reaching $1.889 billion, marking a 3.2% increase over the previous year period. The company also reported a 4.4% increase on a constant currency basis. Diluted earnings per share for the first quarter were $0.84, with adjusted diluted earnings per share at $1.94.
In a statement, Ivan Tornos, Zimmer Biomet's President and Chief Executive Officer, expressed satisfaction with the team's performance, stating, "We are very pleased with the execution, progress, and strong performance the team delivered in the first quarter."
Recent highlights for Zimmer Biomet include receiving U.S. Food and Drug Administration clearance for innovative products such as the ROSA® Shoulder System and the Z1 Femoral Hip Stem. The company also showcased its latest innovations at the 2024 American Academy of Orthopaedic Surgeons annual meeting, demonstrating key growth drivers and recently launched surgical tools.
Moreover, Zimmer Biomet announced partnerships with top pickleball organizations in the United States, emphasizing joint health education and movement in the sport. The company also signed the Global Health Equity Network's Zero Health Gaps Pledge, reaffirming its commitment to advancing health equity.
Additionally, Zimmer Biomet received recognition for its Diversity, Equity, and Inclusion efforts, being acknowledged as one of America's Greatest Workplaces for Women and America's Best Large Employers 2024.
Zimmer Biomet's commitment to Environmental, Social, and Governance (ESG) efforts was recognized by CDP, naming the company a Supplier Engagement Leader for the second consecutive year.
The company is reiterating its full-year 2024 financial guidance and will conduct its first quarter investor conference call on May 2, 2024, at 8:30 a.m. ET. Interested parties can access the audio webcast via Zimmer Biomet's Investor Relations website.
Zimmer Biomet, a global medical technology leader, aims to enhance mobility and improve health through its innovative products and digital technologies. With a legacy of over 90 years, the company continues to prioritize evolution and innovation to deliver high-quality solutions to patients and providers worldwide.
For more information about Zimmer Biomet's product portfolio, operations, and career opportunities, visit their website or follow them on LinkedIn and Twitter.
Please note that this news article is based on the information provided in the original press release by Zimmer Biomet Holdings, Inc.